Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter and nine months ended March 31, 2014 (Palatin’s fiscal third quarter of fiscal 2014), not 2013 Q3 as indicated in the request metadata. The report was filed May 12, 2014.
Business context
Palatin is a clinical-stage biopharmaceutical company developing peptide therapeutics. Its lead program is bremelanotide for female sexual dysfunction (FSD); other programs include PL-3994, melanocortin receptor-1 candidates, and an obesity collaboration with AstraZeneca. The company had no revenue in the nine months ended March 31, 2014.
Financial performance and liquidity
| Metric | Three months ended March 31, 2014 | Nine months ended March 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 for the quarter; $10,361 for nine months |
| Research and development expense | $2.15 million | $8.23 million | $2.94 million and $7.73 million |
| General and administrative expense | $1.21 million | $3.24 million | $1.08 million and $3.14 million |
| Net loss | $1.51 million | $9.61 million | $4.02 million and $16.14 million |
| Net loss per share | $0.01 | $0.09 | $0.04 and $0.17 |
For the nine months, operating expenses were $11.47 million versus $10.88 million in 2013. The lower net loss mainly reflected the prior-year $7.07 million noncash warrant fair-value expense, partly offset by higher R&D spending. The 2014 nine-month result included a $1.85 million tax benefit from selling New Jersey net operating loss carryforwards.
Cash and cash equivalents were $16.72 million at March 31, 2014, down from $19.17 million at June 30, 2013; short-term investments declined from $5.25 million to zero. Current assets were $17.13 million, current liabilities $3.38 million (including $1.00 million of unearned revenue), and working capital approximately $13.75 million. Total liabilities were $3.39 million; the filing shows no material borrowing, with only $2,048 of current capital lease obligations.
Operating cash use was $7.69 million for the nine months, compared with $8.58 million in 2013. Investing activities provided $5.24 million, principally from investment maturities; financing activities used $5,575. Cash decreased $2.45 million overall. The filing does not provide a gross-profit or operating-margin measure meaningful for this pre-revenue business.
Material changes and business developments
- R&D expense rose 6% year over year for the nine-month period, while quarterly R&D fell from $2.94 million to $2.15 million. Management attributed most program spending to bremelanotide.
- On March 31, 2014, Palatin recorded a $1.0 million non-refundable option fee for a potential European bremelanotide license as unearned revenue. On April 30, 2014, after quarter-end, the prospective partner exercised the option to negotiate a definitive agreement; the fee is creditable against a future upfront or initial license payment.
- Palatin reported 39.24 million common shares outstanding at March 31, 2014. Its reported weighted-average shares for loss-per-share purposes were approximately 106.7 million, reflecting the treatment of certain nominal-price warrants in EPS calculations.
Outlook, risks, and contingencies
Management expected to submit complete pivotal Phase 3 protocols for bremelanotide to the FDA and planned to begin the trials as early as the second half of calendar 2014. The program is expected to cost at least $78 million, take at least 18 months from first patient dosing through database lock, and require substantial additional financing. Palatin said it would not begin patient enrollment without adequate funds or commitments to complete the program. Management believed existing resources would fund currently planned operations, including protocol preparation but not Phase 3 enrollment, through at least June 30, 2015.
The company expects further losses and depends on successful development, clinical trials, regulatory approval, commercialization, and access to additional capital or partnerships; no assurance is given that these objectives will be achieved. AstraZeneca was evaluating its obesity program, and Palatin cautioned that continued development or success was uncertain. The filing reported no current legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether Palatin secures sufficient financing or a collaboration to fund the estimated $78 million bremelanotide Phase 3 program, and whether trial timing changes.
- Whether the European option negotiations result in a definitive license agreement and what its financial terms would be.
- Cash burn and liquidity relative to management’s stated June 30, 2015 funding horizon, particularly if development spending increases.
- Progress and results for bremelanotide, PL-3994, MC1R candidates, and AstraZeneca’s obesity program.
- The effect of warrants and other potential shares on dilution; reported EPS weighted-average shares materially exceed common shares outstanding.